Nuveen Asset Management, LLC - AMICUS THERAPEUTICS INC ownership

AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of AMICUS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$15,088,444
+47.5%
1,240,826
+52.3%
0.01%
+25.0%
Q2 2023$10,232,406
+113770.5%
814,682
+0.6%
0.00%
+33.3%
Q1 2023$8,986
-24.5%
810,206
-16.9%
0.00%
-40.0%
Q4 2022$11,908
-99.9%
975,292
-13.7%
0.01%0.0%
Q3 2022$11,805,000
-12.9%
1,130,735
-10.4%
0.01%0.0%
Q2 2022$13,560,000
+29.0%
1,262,563
+15.5%
0.01%
+66.7%
Q1 2022$10,511,000
-29.9%
1,092,670
-25.6%
0.00%
-25.0%
Q4 2021$14,990,000
-16.2%
1,468,151
-9.7%
0.00%
-33.3%
Q3 2021$17,881,000
-4.2%
1,625,472
-16.0%
0.01%0.0%
Q2 2021$18,660,000
-17.3%
1,935,637
-15.2%
0.01%
-14.3%
Q1 2021$22,550,000
-63.3%
2,282,406
-14.2%
0.01%
-66.7%
Q4 2020$61,443,000
+61.3%
2,661,034
-1.3%
0.02%
+40.0%
Q3 2020$38,083,000
-13.0%
2,697,043
-7.1%
0.02%
-16.7%
Q2 2020$43,776,000
+56.2%
2,902,982
-4.3%
0.02%
+28.6%
Q1 2020$28,026,000
-30.7%
3,033,160
-27.0%
0.01%
-6.7%
Q4 2019$40,468,000
+134.2%
4,154,771
+92.8%
0.02%
+114.3%
Q3 2019$17,279,000
-53.1%
2,154,595
-27.0%
0.01%
-53.3%
Q2 2019$36,848,000
+72151.0%
2,952,521
+28451.6%
0.02%
Q4 2016$51,00010,3410.00%
Other shareholders
AMICUS THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Palo Alto Investors LP 10,114,043$116,817,0007.46%
Parametrica Management Ltd 597,279$6,899,0006.86%
Redmile Group, LLC 22,716,086$262,371,0005.96%
Perceptive Advisors 53,118,886$613,524,0004.73%
Asymmetry Capital Management, L.P. 716,709$8,278,0004.39%
CM Management, LLC 450,000$5,198,0003.93%
Avoro Capital Advisors LLC 18,500,000$213,675,0003.64%
Kynam Capital Management, LP 573,699$6,626,0003.54%
SECTORAL ASSET MANAGEMENT INC 1,242,882$14,355,0002.16%
Ghost Tree Capital, LLC 500,000$5,775,0002.07%
View complete list of AMICUS THERAPEUTICS INC shareholders